vs
Bionano Genomics, Inc.（BNGO）与HARVARD BIOSCIENCE INC（HBIO）财务数据对比。点击上方公司名可切换其他公司
HARVARD BIOSCIENCE INC的季度营收约是Bionano Genomics, Inc.的3.0倍（$23.7M vs $8.0M）。HARVARD BIOSCIENCE INC净利率更高（-12.0% vs -99.8%，领先87.8%）。Bionano Genomics, Inc.同比增速更快（-2.6% vs -3.3%）。过去两年HARVARD BIOSCIENCE INC的营收复合增速更高（-1.6% vs -4.8%）
Bionano Genomics是一家基因组技术企业，开发并销售专有光学基因组测绘技术及相关诊断解决方案，可高精度检测基因组大型结构变异，服务全球学术研究机构、生物制药企业与临床诊断实验室，产品应用于肿瘤、罕见病研究等领域。
哈佛生物科学是一家全球生命科学设备开发商、制造商与销售商，其产品主要用于支撑科研开发与药物研发工作，目前该公司在纳斯达克上市，股票交易代码为HBIO。
BNGO vs HBIO — 直观对比
营收规模更大
HBIO
是对方的3.0倍
$8.0M
营收增速更快
BNGO
高出0.7%
-3.3%
净利率更高
HBIO
高出87.8%
-99.8%
两年增速更快
HBIO
近两年复合增速
-4.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $8.0M | $23.7M |
| 净利润 | $-7.9M | $-2.8M |
| 毛利率 | 42.8% | 59.7% |
| 营业利润率 | -107.4% | 7.2% |
| 净利率 | -99.8% | -12.0% |
| 营收同比 | -2.6% | -3.3% |
| 净利润同比 | 60.6% | -15916.7% |
| 每股收益（稀释后） | $-0.12 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BNGOHBIO
| Q4 25 | $8.0M | $23.7M | ||
| Q3 25 | $7.4M | $20.6M | ||
| Q2 25 | $6.7M | $20.4M | ||
| Q1 25 | $6.5M | $21.8M | ||
| Q4 24 | $8.2M | $24.6M | ||
| Q3 24 | $6.1M | $22.0M | ||
| Q2 24 | $7.8M | $23.1M | ||
| Q1 24 | $8.8M | $24.5M |
净利润BNGOHBIO
| Q4 25 | $-7.9M | $-2.8M | ||
| Q3 25 | $-8.5M | $-1.2M | ||
| Q2 25 | $-6.9M | $-2.3M | ||
| Q1 25 | $-3.1M | $-50.3M | ||
| Q4 24 | $-20.1M | $18.0K | ||
| Q3 24 | $-44.2M | $-4.8M | ||
| Q2 24 | $-16.2M | $-2.9M | ||
| Q1 24 | $-31.4M | $-4.7M |
毛利率BNGOHBIO
| Q4 25 | 42.8% | 59.7% | ||
| Q3 25 | 45.7% | 58.4% | ||
| Q2 25 | 51.6% | 56.4% | ||
| Q1 25 | 45.5% | 56.0% | ||
| Q4 24 | 41.9% | 57.1% | ||
| Q3 24 | -139.1% | 58.1% | ||
| Q2 24 | 33.3% | 57.2% | ||
| Q1 24 | 32.2% | 60.3% |
营业利润率BNGOHBIO
| Q4 25 | -107.4% | 7.2% | ||
| Q3 25 | -115.9% | 1.0% | ||
| Q2 25 | -115.8% | -4.0% | ||
| Q1 25 | -131.1% | -228.1% | ||
| Q4 24 | -146.3% | 0.0% | ||
| Q3 24 | -722.9% | -8.5% | ||
| Q2 24 | -219.0% | -9.0% | ||
| Q1 24 | -354.9% | -9.3% |
净利率BNGOHBIO
| Q4 25 | -99.8% | -12.0% | ||
| Q3 25 | -115.4% | -6.0% | ||
| Q2 25 | -101.8% | -11.2% | ||
| Q1 25 | -48.0% | -231.2% | ||
| Q4 24 | -246.5% | 0.1% | ||
| Q3 24 | -728.6% | -21.9% | ||
| Q2 24 | -208.8% | -12.7% | ||
| Q1 24 | -358.3% | -19.1% |
每股收益（稀释后）BNGOHBIO
| Q4 25 | $-0.12 | $-0.06 | ||
| Q3 25 | $-1.59 | $-0.03 | ||
| Q2 25 | $-1.99 | $-0.05 | ||
| Q1 25 | $-1.15 | $-1.14 | ||
| Q4 24 | $-7.05 | $0.01 | ||
| Q3 24 | $-30.92 | $-0.11 | ||
| Q2 24 | $-14.41 | $-0.07 | ||
| Q1 24 | $-35.75 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $8.6M |
| 总债务越低越好 | — | $35.9M |
| 股东权益账面价值 | $44.4M | $13.7M |
| 总资产 | $73.6M | $80.1M |
| 负债/权益比越低杠杆越低 | — | 2.61× |
8季度趋势，按日历期对齐
现金及短期投资BNGOHBIO
| Q4 25 | $3.0M | $8.6M | ||
| Q3 25 | $3.1M | $6.8M | ||
| Q2 25 | $3.6M | $7.4M | ||
| Q1 25 | $3.6M | $5.5M | ||
| Q4 24 | $9.2M | $4.1M | ||
| Q3 24 | $8.8M | $4.6M | ||
| Q2 24 | $10.4M | $4.0M | ||
| Q1 24 | $15.8M | $4.3M |
总债务BNGOHBIO
| Q4 25 | — | $35.9M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $34.9M | ||
| Q1 25 | — | $36.4M | ||
| Q4 24 | — | $37.0M | ||
| Q3 24 | — | $34.9M | ||
| Q2 24 | — | $35.7M | ||
| Q1 24 | — | $35.6M |
股东权益BNGOHBIO
| Q4 25 | $44.4M | $13.7M | ||
| Q3 25 | $49.8M | $14.1M | ||
| Q2 25 | $45.4M | $15.7M | ||
| Q1 25 | $48.2M | $14.8M | ||
| Q4 24 | $35.4M | $63.3M | ||
| Q3 24 | $48.9M | $65.3M | ||
| Q2 24 | $80.3M | $67.2M | ||
| Q1 24 | $82.8M | $68.8M |
总资产BNGOHBIO
| Q4 25 | $73.6M | $80.1M | ||
| Q3 25 | $79.1M | $78.0M | ||
| Q2 25 | $76.0M | $80.1M | ||
| Q1 25 | $78.4M | $79.8M | ||
| Q4 24 | $76.7M | $126.6M | ||
| Q3 24 | $87.4M | $131.2M | ||
| Q2 24 | $129.4M | $128.9M | ||
| Q1 24 | $158.0M | $133.2M |
负债/权益比BNGOHBIO
| Q4 25 | — | 2.61× | ||
| Q3 25 | — | 2.41× | ||
| Q2 25 | — | 2.22× | ||
| Q1 25 | — | 2.45× | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | 0.53× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.52× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.2M | $-96.0K |
| 自由现金流经营现金流 - 资本支出 | — | $-545.0K |
| 自由现金流率自由现金流/营收 | — | -2.3% |
| 资本支出强度资本支出/营收 | — | 1.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $5.5M |
8季度趋势，按日历期对齐
经营现金流BNGOHBIO
| Q4 25 | $-4.2M | $-96.0K | ||
| Q3 25 | $-5.9M | $1.1M | ||
| Q2 25 | $-3.5M | $2.8M | ||
| Q1 25 | $-2.8M | $3.0M | ||
| Q4 24 | $-6.5M | $1.7M | ||
| Q3 24 | $-13.3M | $-842.0K | ||
| Q2 24 | $-21.0M | $-846.0K | ||
| Q1 24 | $-28.1M | $1.4M |
自由现金流BNGOHBIO
| Q4 25 | — | $-545.0K | ||
| Q3 25 | — | $877.0K | ||
| Q2 25 | — | $2.7M | ||
| Q1 25 | — | $2.5M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $-1.7M | ||
| Q2 24 | — | $-1.7M | ||
| Q1 24 | — | $758.0K |
自由现金流率BNGOHBIO
| Q4 25 | — | -2.3% | ||
| Q3 25 | — | 4.3% | ||
| Q2 25 | — | 13.0% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | — | -7.8% | ||
| Q2 24 | — | -7.2% | ||
| Q1 24 | — | 3.1% |
资本支出强度BNGOHBIO
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | 3.5% | ||
| Q1 24 | — | 2.6% |
现金转化率BNGOHBIO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 95.83× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BNGO
暂无分部数据
HBIO
| Instruments Equipment Software And Accessories | $21.6M | 91% |
| Service Maintenance And Warranty Contracts | $2.1M | 9% |
